Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 3
2002 1
2004 1
2006 1
2011 2
2013 2
2014 2
2016 1
2017 1
2020 2
2021 2
2022 1
2023 1
2024 4
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study.
Charlier C, Perrodeau É, Leclercq A, Cazenave B, Pilmis B, Henry B, Lopes A, Maury MM, Moura A, Goffinet F, Dieye HB, Thouvenot P, Ungeheuer MN, Tourdjman M, Goulet V, de Valk H, Lortholary O, Ravaud P, Lecuit M; MONALISA study group. Charlier C, et al. Lancet Infect Dis. 2017 May;17(5):510-519. doi: 10.1016/S1473-3099(16)30521-7. Epub 2017 Jan 28. Lancet Infect Dis. 2017. PMID: 28139432 Free article.
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.
Léna H, Greillier L, Cropet C, Bylicki O, Monnet I, Audigier-Valette C, Falchero L, Vergnenègre A, Demontrond P, Geier M, Guisier F, Hominal S, Locher C, Corre R, Chouaid C, Ricordel C; GFPC 08–2015 ENERGY investigators. Léna H, et al. Among authors: hominal s. Lancet Respir Med. 2025 Feb;13(2):141-152. doi: 10.1016/S2213-2600(24)00264-9. Epub 2024 Oct 29. Lancet Respir Med. 2025. PMID: 39486424 Clinical Trial.
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo).
Vergnenegre A, Monnet I, Ricordel C, Bizieux A, Curcio H, Bernardi M, Corre R, Guisier F, Hominal S, Le Garff G, Bylicki O, Locher C, Geier M, Chouaïd C, Robinet G; GFPC team. Vergnenegre A, et al. Among authors: hominal s. Lung Cancer. 2023 Apr;178:191-197. doi: 10.1016/j.lungcan.2023.02.020. Epub 2023 Feb 27. Lung Cancer. 2023. PMID: 36868180 Clinical Trial.
Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting.
Falchero L, Meyer N, Molinier O, Al Freijat F, Pegliasco H, Lecuyer E, Stoven L, Belmont L, Loutski S, Maincent C, Blanchet-Legens AS, Mairovitz A, Meniai F, Hominal S, Letierce A, Morel H, Debieuvre D. Falchero L, et al. Among authors: hominal s. Eur J Cancer. 2024 Oct;210:114277. doi: 10.1016/j.ejca.2024.114277. Epub 2024 Aug 14. Eur J Cancer. 2024. PMID: 39168000
[Carcinomatous lymphangitis].
Hominal S, Falchero L, Perol M, Guérin JC. Hominal S, et al. Presse Med. 1999 May 15;28(18):979-84. Presse Med. 1999. PMID: 10366939 Review. French.
LIBELULE: A Randomized Phase III Study to Evaluate the Clinical Relevance of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer.
Swalduz A, Schiffler C, Curcio H, Ambasager B, Le Moel G, Debieuvre D, Dot JM, Duruisseaux M, Fournel P, Odier L, Demolombe S, Bizieux-Thaminy A, Peytier A, Schott R, Hominal S, Tissot C, Bombaron P, Metzger S, Donnat M, Ortiz-Cuaran S, Rosenfeld N, Pipinikas C, Saintigny P, Pérol M. Swalduz A, et al. Among authors: hominal s. J Thorac Oncol. 2025 Apr;20(4):437-450. doi: 10.1016/j.jtho.2024.12.011. Epub 2024 Dec 16. J Thorac Oncol. 2025. PMID: 39694415 Free article. Clinical Trial.
Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trial.
Bylicki O, Guisier F, Scherpereel A, Daniel C, Swalduz A, Grolleau E, Bernardi M, Hominal S, Prevost JB, Pamart G, Marques MH, Cloarec N, Deshayes S, Raimbourg J, Veillon R, Oulkhouir Y, Audigier Valette C, Subtil F, Chouaïd C, Greillier L; GFPC. Bylicki O, et al. Among authors: hominal s. Lung Cancer. 2024 Aug;194:107866. doi: 10.1016/j.lungcan.2024.107866. Epub 2024 Jun 29. Lung Cancer. 2024. PMID: 38972083 Free article.
First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing ≥ 50% PD-L1 (ESCKEYP GFPC 05-2018).
Corre R, Decroisette C, Auliac JB, Falchero L, Curcio H, Amrane K, Perol M, Hominal S, Vieillot S, Huchot E, Desage AL, Bernardi M, Veillon R, Doubre H, Bota S, Legarff G, Justeau G, Bylicki O, Roa M, Descourt R, Chouaïd C, Greillier L. Corre R, et al. Among authors: hominal s. Clin Lung Cancer. 2025 Jun;26(4):331-337. doi: 10.1016/j.cllc.2025.03.001. Epub 2025 Mar 4. Clin Lung Cancer. 2025. PMID: 40122771
[Pleural mesothelioma].
Monnet I, Hominal S. Monnet I, et al. Among authors: hominal s. Rev Pneumol Clin. 2000 Dec;Suppl 3:24-5. Rev Pneumol Clin. 2000. PMID: 11280975 Review. French. No abstract available.
24 results